Aims: It is often assumed that β-blockers, e.g. metoprolol (METO), induce erectile dysfunction (ED) in men. However, cardiovascular diseases can also induce ED and there is also the possibility that psychological factors, such as fear of the disease and side effects of the prescribed drug, may also induce ED. Thus, it is often assumed that β-blockers induce ED in a large percentage of men, but this statement is not well validated and the role of the pharmacologic effect of METO per se on the occurrence of ED is largely unknown. To get an answer we selected 114 men (age 57 ± 4.7 years) without ED but with newly diagnosed arterial hypertension, and who could be treated with METO. Methods: METO (100 mg/day) was given as a retard formulation. The hypertensive men were randomized into 3 groups. In group 1 patients were fully informed (they knew that the drug was METO and that it might induce ED). In group 2 patients were partially informed (they knew that the drug was METO, but were not informed that it might induce ED). In group 3 patients were not informed either about the drug used or about the possible occurrence of ED. The first phase of the study lasted 60 days. After 60 days the incidence of ED was 32% in group 1, 13% in group 2, and 8% in group 3 (p < 0.01). All patients with ED entered the second, cross-over, double-blind phase of the study. METO was continued at unchanged dosage, and tadalafil (20 mg) and a placebo were given to treat ED. Results: Both treatments were equally effective. Conclusion: Prejudice about the possible occurrence, i.e. the Hawthorne effect, of ED with METO facilitates the occurrence of this side effect in hypertensive men. Since the etiology of this ED is largely psychological, it is not surprising that placebo is as effective as tadalafil in reversing this side effect.

Keywords:
Metoprolol, β-Blockers, Erectile dysfunction
1.
Korenman SG: New insights into erectile dysfunction: a practical approach. Am J Med 1998;105:135–144.
2.
NIH Consensus Conference: Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83–90.
3.
Srilatha B, Adaikan PG, Arulkumaran S, et al: Sexual dysfunction related to antihypertensive agents: results from the animal model. Int J Impot Res 1999;11:107–113.
4.
Keene LC, Davies PH: Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999;18:5–24.
5.
Rosen RC, Kostis JB, Jekelis A, et al: Sexual sequelae of antihypertensive drugs: treatment effects of self-report and physiological measures in middle-aged male hypertensives. Arch Sex Behav 1994;23:135–152.
6.
Franzen D, Metha A, Seifert N, et al: Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study. Int J Impot Res 2001;13:348–351.
7.
Silvestri A, Galetta P, Cerquetani E, et al: Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. Eur Heart J 2003;24:1928–1932.
8.
Jackson G: Erectile dysfunction: a marker of silent coronary artery disease. Eur Heart J 2006;27:2613–1614.
9.
Giuliano F: Phosphodiesterase type 5 inhibition in erectile dysfunction: an overview. Eur Heart J Suppl H 2002;4:H7–H12.
10.
Gillespie R: Manufacturing Knowledge: A History of the Hawthorne Experiments. Cambridge, Cambridge University Press, 1991.
11.
Rosen RC, Riley A, Wagner G, et al: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1998;81:424–431.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.